“The initiation of dosing in this study marks a major milestone for NiKang, as NKT3447 is the first of our pipeline programs targeting the cell cycle to begin clinical evaluation,” said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang. “We have strong conviction that CDK2...